Search Tag: Radiopharmaceuticals

2022 07 Nov

Fusion Pharmaceuticals Inc, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines announced the appointment of Dmitri Bobilev, M.D., as chief medical officer. "We are pleased to welcome Dmitri to Fusion's leadership team at a time when Fusion has three Phase 1 novel targeted alpha therapy...Read more

2013 30 May

The Asia-Pacific radiopharmaceutical market was valued at $500.8 million in 2012 and is poised to reach $824.9 million by 2017 at a Compound Annual Growth Rate (CAGR) of 10.5 percent, according to a report from Markets and Markets. The "Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market & Stable Isotopes [SPECT/PET Radioisotopes (Technetium,...Read more

2013 15 May

Research and Markets has published  "Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017"  The global radiopharmaceuticals market was valued at $3.8...Read more

2013 03 May

The North American radiopharmaceuticals market was valued at $1.9 billion in 2012 and is poised to reach $2.7 billion by 2017 at a CAGR of 7.2 percent, according to a new report from Reportlinker.com, "North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy...Read more

2013 29 Apr

Markets and Markets has released a new report on the nuclear medicine and radiopharmaceuticals market. The Nuclear Medicine/ Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast...Read more

2013 24 Apr

Researchers at the University of California, San Diego School of Medicine have shown that a new imaging dye is an effective agent in detecting and mapping cancers that have reached the lymph nodes. The radioactive dye, called Technetium Tc-99m tilmanocept, successfully identified cancerous lymph nodes and did a better job of marking cancers than the...Read more

2013 16 Apr

Navidea Biopharmaceuticals, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, has announced U.S. Food and Drug Administration (FDA) approval of Lymphoseek® (technetium Tc 99m tilmanocept) Injection, which is indicated for use in lymphatic mapping procedures to assist in the localisation of lymph nodes draining a primary...Read more

2013 08 Apr

Markets and Markets has announced the release of a report on the European nuclear medicine market over the forecast period 2012-2017. The European radiopharmaceutical market was valued at $1.1 billion in 2012 and is poised to reach $1.6 billion by 2017 at a CAGR of 6.8%. The radioisotopes market is categorised into diagnostic and therapeutic...Read more